Director Julianne Bruno filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting 33,442 shares of common stock in InMed Pharmaceuticals Inc. received through a merger effective November 6, 2026.

Key Highlights

  • Reporting person: Julianne Bruno, identified as a Director of the issuer.
  • Shares held: 33,442 shares of common stock, held directly, as reported in Table I.
  • Source of shares: Shares were received in connection with the Merger, in exchange for shares of Pre-Merger Mentari Therapeutics, Inc. common stock, at an exchange ratio of 0.20065 restricted shares of the issuer's common stock per share of Pre-Merger Mentari restricted common stock.
  • Vesting restriction: Of the 33,442 shares, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the reporting person's continued service to the issuer on each vesting date.
  • Event date: The date of event requiring the statement was November 6, 2026, the effective time of the Merger.
  • No derivative securities: Table II reports no derivative securities beneficially owned.

Merger Background and Bruno's Initial Ownership Stake at InMed/Mentari

According to the filing, effective November 6, 2026, Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc., traded on NASDAQ:MTRI), merged with and into Mentari Therapeutics, Inc., a Delaware corporation referred to as Pre-Merger Mentari, with Pre-Merger Mentari continuing as a wholly owned subsidiary of the issuer and the surviving corporation of the first merger. Immediately thereafter, the filing states, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the issuer, with that entity surviving under the name Mentari Therapeutics Operating Company LLC.

As a result of these transactions, the filing discloses that Julianne Bruno received 33,442 shares of the issuer's common stock in exchange for shares of Pre-Merger Mentari common stock held prior to the merger. The applicable exchange ratio was 0.20065 restricted shares of the issuer's common stock for each share of Pre-Merger Mentari restricted common stock. Of the total shares reported, 23,689 remain subject to forfeiture restrictions, according to the filing, and are scheduled to vest in equal monthly installments through August 13, 2029, contingent on the reporting person's continued service to the issuer on each vesting date.

The form was signed by Jerad G. Seurer as attorney-in-fact for Julianne Bruno on November 12, 2026, pursuant to a Power of Attorney listed as Exhibit 24. No derivative securities were reported in Table II of the filing.

What Was Disclosed

Julianne Bruno filed an initial beneficial ownership statement as a newly reporting Director of InMed Pharmaceuticals Inc. (NASDAQ:MTRI), disclosing 33,442 directly held common shares received through a two-step merger effective November 6, 2026, with 23,689 of those shares subject to ongoing vesting restrictions through August 13, 2029.